EGI
ENTA icon

EAM Global Investors’s Enanta Pharmaceuticals ENTA Stock Holding History

EAM Global Investors’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-20,824
Closed -$1.56M – 228
2021
Q4 		$1.56M Buy
+20,824
New +$1.63M 0.28% 177
2018
Q3 		– Sell
-7,912
Closed -$917K – 165
2018
Q2 		$917K Sell
7,912
-3,524
-31% -$352K 0.45% 131
2018
Q1 		$925K Buy
+11,436
New +$880K 0.48% 115

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

EAM Global Investors's ENTA Position: Q1 2022 in Review

EAM Global Investors sold out of Enanta Pharmaceuticals (ENTA) in Q1 2022, closing a stake of 20,824 shares — an estimated $1.56M sold.

EAM Global Investors first reported a position in ENTA in Q1 2018 and held it in 3 quarters. The position peaked at $1.56M in Q4 2021. 169 funds tracked by Wall St. Rank hold ENTA as of Q1 2022.

  • EAM Global Investors reported no remaining Enanta Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • EAM Global Investors sold 20,824 Enanta Pharmaceuticals shares in Q1 2022, an estimated $1.56M.
  • EAM Global Investors first reported a position in Enanta Pharmaceuticals in Q1 2018 and held it in 3 quarters.
  • EAM Global Investors's Enanta Pharmaceuticals position peaked at $1.56M in Q4 2021.
  • 169 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2022.

Based on EAM Global Investors's 13F filing for Q1 2022, filed 13 May 2022.